In adult patients with myocardialinfarction and anemia, did a liberal transfusion strategy, as compared with a restrictive transfusion strategy, result in a lower incidence of myocardialinfarction or death?
Healthcare Resource Utilization Following Acute MyocardialInfarction Findings from RECORD-MI Registry: Healthcare Utilization after MyocardialInfarction. The contemporary healthcare resource utilization following an acute myocardialinfarction (MI) is not well known. All patients admitted due to MI between 01/2015 and 12/2021 across 28 hospitals in the Baylor Scott & White Health system were studied. Patient characteristics and outcomes, including all-cause and cardiovascular (CV) rehospitalizations, emergency department (ED) visits, and outpatient visits were evaluated. Of 6804 patients admitted due to MI, 6556 were discharged alive. Median age was 69 years, 60% were male, and 77% had non-ST elevation MI (NSTEMI); 17% (1090) had multivessel disease. The number of patients with first all
Myocardialinfarction (MI) - secondary prevention CKS is only available in the UK | NICE CKS is only available in the UKThe NICE Clinical Knowledge Summaries (CKS) site is only available to users in the UK, Crown Dependencies and British Overseas Territories.CKS content is produced by Clarity Informatics Limited. It is available to users outside the UK via subscription from the Prodigy website.If
Effect of Empagliflozin on Heart Failure Outcomes After Acute MyocardialInfarction: Insights From the EMPACT-MI Trial Empagliflozin reduces the risk of heart failure events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, and in those with prevalent heart failure irrespective of ejection fraction. While EMPACT-MI showed empagliflozin does not reduce the risk of the composite of hospitalization of heart failure and all-cause mortality, the impact of empagliflozin on first and recurrent heart failure events in patients after myocardialinfarction is unknown. EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardialinfarction at risk for heart failure based on newly developed left
Effects of beta-blockers on quality of life and well-being in patients with myocardialinfarction and preserved left ventricular function-a prespecified substudy from REDUCE-AMI. In the Randomized Evaluation of Decreased Usage of Beta-Blockers after Acute MyocardialInfarction (REDUCE-AMI) study, long-term beta-blocker use in patients after acute myocardialinfarction (AMI) with preserved left and 11-13 months after AMI in 4080 and 806 patients, respectively. We report results from intention-to-treat and on-treatment analyses for the overall population and relevant subgroups using Wilcoxon rank sum test and adjusted ordinal regression analyses. Of the 4080 individuals reporting EQ-5D (median age 64 years, 22% female), 2023 were randomized to beta-blockers. The main outcome, median EQ-5D
BMI and Deescalation From Ticagrelor to Clopidogrel in Patients With Acute MyocardialInfarction: A Post Hoc Analysis of the TALOS-AMI Trial. The potential benefits of P2Y12 inhibitor deescalation for acute myocardialinfarction after percutaneous coronary intervention may be influenced by body mass index (BMI). To investigate the association of BMI on deescalation outcomes after 12 months the TALOS-AMI (Ticagrelor vs Clopidogrel in Stabilized Patients with Acute MyocardialInfarction) randomized clinical trial. Data were collected from February 14, 2014, to December 31, 2018, with follow-up to January 21, 2021. Analyses were conducted from December 1, 2021, to August 21, 2024. Among 2697 trial participants from 32 centers in South Korea, 2686 participants whose BMI data were available were
The prognostic value of global longitudinal strain in patients with myocardialinfarction and preserved ejection fraction - a prespecified substudy of the REDUCE-AMI trial. The REDUCE-AMI trial showed that beta-blockers in patients with preserved left ventricular ejection fraction (LVEF) after acute myocardialinfarction (AMI) had no effect on mortality or cardiovascular outcomes. The aim of this substudy was to evaluate whether global longitudinal strain (GLS) is a better prognostic marker than LVEF, and if beta-blockers have a beneficial effect in patients with decreased GLS. REDUCE-AMI was a registry-based randomized clinical trial. Conventional echocardiographic parameters and GLS were obtained and a likelihood ratio test between models adjusted for age, sex, hypertension, smoking, diabetes
Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute MyocardialInfarction: The CTS-AMI Randomized Clinical Trial. Tongxinluo, a traditional Chinese medicine compound, has shown promise in in vitro, animal, and small human studies for myocardialinfarction, but has not been rigorously evaluated in large randomized clinical trials. To investigate whether Tongxinluo could improve clinical outcomes in patients with ST-segment elevation myocardialinfarction (STEMI). Randomized, double-blind, placebo-controlled clinical trial was conducted among patients with STEMI within 24 hours of symptom onset from 124 hospitals in China. Patients were enrolled from May 2019 to December 2020; the last date of follow-up was December 15, 2021. Patients were randomized 1:1
agrees with the plan but given the patient’s obvious myocardialinfarction she suggests you transfuse the patient up to a hemoglobin of 10 g/dL. When you ask your attending, you are told this is not necessary and that there is prior evidence that restrictive transfusion strategies are just as efficacious (even in the setting of an acute MI), citing a prior journal club on this topic. You successfully Restrictive vs. Liberal Transfusion in MyocardialInfarction Skip to contentSkip to searchSkip to footerEmergency MedicineOpen MenuRestrictive vs. Liberal Transfusion in Myocardial InfarctionBy Paige • April 2, 2024Washington University Emergency Medicine Journal Club- April 2024VignetteYou’re working a shift on community medicine rotation in a medium-sized community-based ED one afternoon when
HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute MyocardialInfarction(HELP-MI SWEDEHEART)Design and rationale of a cluster randomized, crossover, registry-based clinical trial. The role of Helicobacter pylori (H. pylori) screening and eradication on reducing upper gastrointestinal bleeding (UGIB) complications after acute myocardialinfarction (MI ) is uncertain. The HELicobacter Pylori screening to prevent gastrointestinal bleeding in patients with acute MI (HELP-MI SWEDEHEART) trial aims to determine whether systematic H. pylori screening compared to usual care reduces UGIB, mortality, and cardiovascular outcomes after MI. A cluster randomized, crossover, registry-based clinical trial using SWEDEHEART as trial platform for study population definition
Non-ST-elevation myocardialinfarction Skip to main contentSkip to searchLog inEnglishWe're showing you BMJ Best Practice in English. Click here to change your language.Please note: changing your language may affect units of measurement for drug dosages, drug names, spelling and choice of guidelinesSearchSearchNon-ST-elevation myocardialinfarction MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:4 Sep 2023Last updated:28 Sep 2023SummaryNon-ST-elevation myocardialinfarction (NSTEMI) is part of the acute coronary syndrome spectrum. Usually caused by a partial or near-complete occlusion of a coronary artery resulting in compromised blood flow to myocardium with subsequent myocardial injury or infarction as demonstrated by elevation in troponin.There are differences
ST-elevation myocardialinfarction Skip to main contentSkip to searchAbout usHelpSubscribeAccess through your institutionLog inBMJ Best PracticeSearchSearchSelect languageST-elevation myocardialinfarction MENULog in or subscribe to access all of BMJ Best PracticeLast reviewed:13 Aug 2023Last updated:12 Sep 2023SummaryST-elevation myocardialinfarction (STEMI) presents with central chest pain and/or residual angina symptoms.DefinitionAcute myocardialinfarction is myocardial cell death that occurs because of a prolonged mismatch between perfusion and demand. In the case of ST-elevation myocardialinfarction (STEMI) this is caused predominantly by complete atherothrombotic occlusion of a coronary artery.In the appropriate clinical context, a STEMI is diagnosed clinically when there is new
cohort study published in the BMJ has shown a small increased relative risk of ischaemic stroke (stroke) and myocardialinfarction (MI) in users of combined hormonal contraception (CHC) and some progestogen-only pills (POP). A small increase in the relative risk of stroke was also seen with the contraceptive implant. It is important to note that the overall risk of stroke and MI remains low and must FSRH Statement: Response to study by Yonis et al. Stroke and myocardialinfarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study 1 FSRH Statement: Response to study by Yonis et al. Stroke and myocardialinfarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study. February 2025 A Danish nationwide prospective
with acute myocardialinfarction and multivessel disease. Probabilistic sensitivity analysis showed consistent results and the likelihood iteration of cost-effectiveness in FFR-guided PCI was 97%. When transition probabilities from the pairwise meta-analysis of the FLOWER-MI and FRAME-AMI trials were used, FFR-guided PCI was more cost-effective than angiography-guided PCI in the Korean, US, and European Cost-Effectiveness of Fractional Flow Reserve-Guided Treatment for Acute MyocardialInfarction and Multivessel Disease: A Prespecified Analysis of the FRAME-AMI Randomized Clinical Trial. Complete revascularization by non-infarct-related artery (IRA) percutaneous coronary intervention (PCI) in patients with acute myocardialinfarction is standard practice to improve patient prognosis. However
A review regarding the article 'Traditional Chinese medicine compound (Tongxinluo) and clinical outcomes of patients with acute myocardialinfarction the CTS-AMI randomized clinical trial'. Tongxinluo, a traditional Chinese medicine compound, has shown promise in improving outcomes for patients with ST-segment elevation myocardialinfarction (STEMI). This randomized, double-blind, placebo
Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardialinfarction: A PACMAN-AMI randomized clinical trial substudy. The effects of protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on endothelial function as assessed by flow-mediated dilation (FMD) in patients with acute myocardialinfarction (AMI) are unknown. Therefore, we aimed to investigate , for the randomized-controlled, double-blind, PACMAN-AMI trial, which compared the effects of biweekly alirocumab 150 mg vs. placebo added to rosuvastatin. Brachial artery FMD was measured at 4 and 52 weeks, and intracoronary imaging at baseline and 52 weeks. 139/173 patients completed the substudy. There was no difference in FMD at 52 weeks in the alirocumab (n = 68, 5.44 ± 2.24%) versus placebo (n = 71, 5.45
Pressure-Controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute MyocardialInfarction: The PiCSO-AMI-I Trial. Primary percutaneous coronary intervention (pPCI) has improved clinical outcomes in patients with ST-segment-elevation myocardialinfarction. However, as many as 50% of patients still have suboptimal myocardial reperfusion and experience extensive myocardial necrosis . The PiCSO-AMI-I trial (Pressure-Controlled Intermittent Coronary Sinus Occlusion-Acute MyocardialInfarction-I) evaluated whether PiCSO therapy can further reduce myocardialinfarct size (IS) in patients undergoing pPCI. Patients with anterior ST-segment-elevation myocardialinfarction and Thrombolysis in MyocardialInfarction flow 0-1 were randomized at 16 European centers to PiCSO-assisted pPCI
a double-blind design will compare initial P2Y12 inhibitor treatment strategies in patients with CS-AMI of (A) intravenous cangrelor and (B) ticagrelor administered as crushed tablets at a loading dose of 180 mg. The primary clinical endpoint is a composite of all-cause death, myocardialinfarction (MI), or stroke within 30 days. The main secondary endpoints are (1) the net clinical endpoint, defined Cangrelor versus crushed ticagrelor in patients with acute myocardialinfarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial. Cardiogenic shock (CS) is a devastating and fatal complication of acute myocardialinfarction (AMI). CS can affect the pharmacokinetics and pharmacodynamics of medications. The unique properties of cangrelor make
Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardialinfarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. Among patients with myocardialinfarction (MI) with preserved left ventricular ejection fraction (LVEF), the REDUCE-AMI trial did not demonstrate a benefit of beta -blocker vs. no beta-blocker treatment on all-cause mortality and recurrent myocardialinfarction. The aim of this pre-specified sub-study was to investigate effects of beta-blockers on self-reported symptoms of anxiety and depression. In this parallel-group, open-label, registry-based randomized trial, assessments with the Hospital Anxiety and Depression Scale were obtained at hospitalization and two
Lesion-Level Effects of LDL-C-Lowering Therapy in Patients With Acute MyocardialInfarction: A Post Hoc Analysis of the PACMAN-AMI Trial. Previous studies investigated atherosclerotic changes induced by lipid-lowering therapy in extensive coronary segments irrespective of baseline disease burden (a vessel-level approach). To investigate the effects of lipid-lowering therapy on coronary lesions with advanced atherosclerotic plaque features and presumably higher risk for future events. The PACMAN-AMI randomized clinical trial (enrollment: May 2017 to October 2020; final follow-up: October 2021) randomized patients with acute myocardialinfarction to receive alirocumab or placebo in addition to high-intensity statin therapy. In this post hoc lesion-level analysis, nonculprit lesions were identified